Alphatec (NASDAQ:ATEC) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Alphatec (NASDAQ:ATEC) in a report issued on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $20.00 price target on the medical technology company’s stock.

A number of other research analysts also recently commented on the stock. Barclays reissued an “overweight” rating and set a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. JPMorgan Chase & Co. began coverage on shares of Alphatec in a research report on Friday, October 24th. They set an “overweight” rating and a $19.00 target price on the stock. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Friday, August 1st. Finally, Wells Fargo & Company raised their target price on shares of Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.44.

Alphatec Trading Up 0.4%

ATEC stock opened at $16.65 on Tuesday. The company has a market capitalization of $2.46 billion, a PE ratio of -14.73 and a beta of 1.05. Alphatec has a 12 month low of $5.20 and a 12 month high of $17.11. The firm’s 50-day moving average is $15.20 and its 200 day moving average is $13.12. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to analysts’ expectations of $178.85 million. The company’s revenue for the quarter was up 27.5% on a year-over-year basis. During the same period last year, the business posted ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Alphatec will post -1.08 EPS for the current year.

Insiders Place Their Bets

In other news, EVP David Sponsel sold 70,000 shares of the firm’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $16.18, for a total value of $1,132,600.00. Following the sale, the executive vice president directly owned 461,861 shares in the company, valued at approximately $7,472,910.98. This trade represents a 13.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Scott Lish sold 6,323 shares of Alphatec stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $16.01, for a total transaction of $101,231.23. Following the completion of the sale, the chief operating officer owned 658,707 shares of the company’s stock, valued at $10,545,899.07. This trade represents a 0.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 850,575 shares of company stock worth $12,902,127. Insiders own 22.80% of the company’s stock.

Institutional Trading of Alphatec

Institutional investors have recently bought and sold shares of the stock. Osterweis Capital Management Inc. acquired a new stake in Alphatec in the 2nd quarter worth approximately $37,000. Larson Financial Group LLC acquired a new stake in Alphatec in the 1st quarter worth approximately $54,000. Nisa Investment Advisors LLC boosted its stake in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after purchasing an additional 1,045 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in Alphatec in the 3rd quarter worth approximately $120,000. Finally, Destiny Wealth Partners LLC acquired a new stake in Alphatec in the 3rd quarter worth approximately $145,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.